August 14, 2012 04:10 ET

Top 50 Pharmaceutical Companies Will Generate Nearly $1 Trillion in Annual Revenues

ROCKVILLE, MD--(Marketwire - Aug 14, 2012) - has announced the addition of "Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016," to their collection of Construction Company Reports market reports. For more information, visit

There are an estimated 724 projects in development from the top 50 pharmaceutical companies. Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors? In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies that produce the lion's share of industry revenues.

While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.

The industry has struggled in recent years but many observers see biopharmaceutical as the key to continued success for market leaders. Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses. The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.

For more information, visit

About is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. Moreover,'s Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance. For more information, call Will Gray at 240-747-3008 or visit

Contact Information

  • Contact:
    Will Gray
    Email Contact